Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpre
- PDF / 97,278 Bytes
- 1 Pages / 595.276 x 790.866 pts Page_size
- 11 Downloads / 180 Views
ERRATUM
Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 Bojana Milojkovic Kerklaan • Veronique Die´ras • Christophe Le Tourneau • Marja Mergui-Roelvink Alwin D. R. Huitema • Hilde Rosing • Jos H. Beijnen • Sandrine Marreaud • Anne-Sophie Govaerts • Martine J. Piccart-Gebhart • Jan H. M. Schellens • Ahmad Awada
•
Published online: 18 January 2013 Ó Springer-Verlag Berlin Heidelberg 2013
Erratum to: Cancer Chemother Pharmacol (2013) 71:53–62 DOI 10.1007/s00280-012-1972-1 Unfortunately, one of the co-author’s (Bojana Milojkovic Kerklaan) family name was published wrongly in the original version of the article. The correct family name is Milojkovic Kerklaan.
The online version of the original article can be found under doi:10.1007/s00280-012-1972-1. B. Milojkovic Kerklaan M. Mergui-Roelvink J. H. M. Schellens Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands V. Die´ras C. Le Tourneau Department of Medical Oncology, Institute Curie, Paris, France A. D. R. Huitema H. Rosing J. H. Beijnen Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands J. H. Beijnen J. H. M. Schellens Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Utrecht, The Netherlands S. Marreaud A.-S. Govaerts A. Awada NDDG/BCG Group, European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium M. J. Piccart-Gebhart A. Awada (&) Institute Jules Bordet, Brussels, Universite´ Libre de Bruxelles, Brussels, Belgium e-mail: [email protected]
123
Data Loading...
